Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l

Blood

Volumn 121, Issue 13, 2013, Pages 2533-2541

  Deshpande, Aniruddha J ^a,b,c   Chen, Liying ^a,b,d   Fazio, Maurizio ^a,e   Sinha, Amit U ^a,b,c   Bernt, Kathrin M ^a,b,f   Banka, Deepti ^a,b   Dias, Stuart ^a,b   Chang, Jenny ^a,b,c   Olhava, Edward J ^g   Daigle, Scott R ^g   Richon, Victoria M ^g   Pollock, Roy M ^g   Armstrong, Scott A ^a,b,c,h  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f Children's Hospital Colorado   (United States)

^g EPIZYME INC   (United States)

^h HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF6 PROTEIN; BETA ACTIN; DNA; DOT1L HISTONE METHYLTRANSFERASE; ENZYME INHIBITOR; EPZ 0004777; HISTONE H3; HISTONE METHYLTRANSFERASE; LYSINE; LYSINE 79; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ADENOSINE; CARBANILAMIDE DERIVATIVE; DOT1L PROTEIN, MOUSE; DRUG DERIVATIVE; EPZ004777; HISTONE LYSINE METHYLTRANSFERASE; KINESIN; METHYLTRANSFERASE; MLL PROTEIN, MOUSE; MLLT4 PROTEIN, MOUSE; MYOSIN; ONCOPROTEIN;

ACUTE MYELOID LEUKEMIA; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA CONTENT; DRUG EXPOSURE; ERYTHROCYTE COUNT; FLOW CYTOMETRY; FUSION GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA; LEUKEMOGENESIS; LEUKOCYTE COUNT; MICROARRAY ANALYSIS; MLL AF6 FUSION GENE; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; TRANSFORMED CELL; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ADENOSINE; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; KINESIN; LYSINE; METHYLTRANSFERASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; MYOSINS; ONCOGENE PROTEINS, FUSION; PHENYLUREA COMPOUNDS;

MLCS; MLOWN;

EID: 84878383491     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-465120     Document Type: Article

References (29)

1. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev Genet. 1998;32:495-519.
2. Daser A, Rabbitts TH. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol. 2005; 15(3):175-188.
3. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annual Review of Pathology: Mechanisms of Disease. 2012;7(1): 283-301.
4. Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23(8):1490-1499.
5. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11): 823-833.
6. Lin C, Smith ER, Takahashi H, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell. 2010;37(3):429-437.
7. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell. 2010;17(2): 198-212.
8. Mohan M, Herz HM, Takahashi YH, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24(6):574-589.
9. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5): 355-368.
10. Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22(24):3403-3408.
11. Chang MJ, Wu H, Achille NJ, et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010;70(24):10234-10242.
12. Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20(1):66-78.
13. Jo SY, Granowicz EM, Maillard I, et al. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood. 2011;117(18):4759-4768.
14. Nguyen AT, Taranova O, He J, et al. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011; 117(25):6912-6922.
15. Chen L, Deshpande AJ, Banka D, et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1 [published online ahead of print Nov 9, 2012]. Leukemia. 2012.
16. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
17. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/ MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-2496.
18. Pigazzi M, Masetti R, Bresolin S, et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia. 2011;25(3):560-563.
19. Liedtke M, Ayton PM, Somervaille TC, et al. Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. Blood. 2010;116(1):63-70.
20. Reich M, Liefeld T, Gould J, et al. GenePattern 2.0. Nat Genet. 2006;38(5):500-501.
21. Wang QF, Wu G, Mi S, et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood. 2011;117(25):6895-6905.
22. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110(13):4445-4454.
23. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121(2):167-178.
24. Yamamoto T, Harada N, Kano K, et al. The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells. J Cell Biol. 1997;139(3):785-795.
25. Mandai K, Nakanishi H, Satoh A, et al. Afadin: a novel actin filament-binding protein with one PDZ domain localized at cadherin-based cell-to-cell adherens junction. J Cell Biol. 1997;139(2): 517-528.
26. Buchert M, Poon C, King JA, et al. AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartment. J Cell Physiol. 2007; 210(1):212-223.
27. Deshpande AJ, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012;33(11):563-570.
28. Tan J, Muntean AG, Hess JL. PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget. 2010;1(6):461-465.
29. Yao Y, Chen P, Diao J, et al. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc. 2011;133(42):16746-16749.